Devices, digital health, and the technology changing how care is delivered.
GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any job losses.
The founders of contract research organization Quartesian have reunited to form Acrosian, a CRO designed to be purpose-built for the AI era.
Colorectal cancer blood test maker Guardant Health has teamed up with “Grey’s Anatomy” star Patrick Dempsey for a new, highly emotional video.
Medical device maker Boston Scientific has been a prolific dealmaker this year but is now taking a step back as it looks to make changes internally.
Lakshmi Halasyamani, chief clinical officer at Endeavor Health, thinks value-based care isn’t really about payment models. To her, this work centers on understanding patients’ clinical, social and financial circumstances well enough to make care plans that actually work for their lives. The post Why Endeavor Health Refuses to Silo Its Value-Based Care Strategy appeared first on MedCity News .
Abbott will market Freenome’s SimpleScreen CRC test in the U.S., alongside its Cologuard stool test. SimpleScreen will compete with Guardant Health’s Shield blood test for colorectal cancer screening.
A new biotech has come into view with a $118 million series B and a vision for making the front of the eye front-of-mind.
Atrial fibrillation (AF) is the most common sustained arrhythmia in the United States, with a nation-wide prevalence projected to reach 12.1 million by 2030.1 AF is a major driver of adverse clinical outcomes, including stroke, dementia, myocardial infarction, sudden cardiac death, heart failure, chronic kidney disease, and all-cause death.
The device, bought during Boston Scientific’s acquisition of Silk Road Medical, has a risk of catheter tip separation during use.
Aidoc is bringing a system that can interpret images and make draft reports for radiologists to the FDA as the medtech industry awaits clarity on regulation of generative AI. Ensuring safety is paramount, said CEO Elad Walach.
Rare disease biotech Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital-sponsored Research Alliance Corporation III (RACC) to fund a rare genetic disease candidate.
The question is not whether the technology is impressive. The question is whether it shows up at the right time, with the right information, inside the workflow where the decision is being made. Anything else is just another report. The post How AI Inside Clinical Workflows Is Unlocking Patient Throughput appeared first on MedCity News .
As patients increasingly bring AI chatbot advice into exam rooms, where does liability land when that advice goes wrong? Health law attorney Meghan O’Connor said the answer still isn’t clear, but silence is the riskiest response for providers. The post What Happens When Patients Trust AI Over Their Doctor? appeared first on MedCity News .
Apnimed has detailed its plans for an initial public offering, with the biotech intending to raise as much as $160 million to fund the launch of its sleep apnea pill.
After signing a deal worth up to $486 million with Italian biopharma Chiesi to develop its pulmonary arterial hypertension (PAH) candidate seralutinib in 2024, Gossamer Bio has ended the collaboration and licensing agreement.
In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.
AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.
Labcorp is launching the Marker by Labcorp Genetic Health Panel, a new direct-to-consumer genetic testing tool that analyzes 163 genes to determine patients’ risk of over 100 hereditary health conditions.
Crystalys’s dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecule that Sobi added to its pipeline through a $950 million acquisition. The post Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug appeared first on MedCity News .
Candid’s Series D round was led by Sixth Street Growth, with participation from Oak HC/FT, 8VC and Y Combinator. The post Candid Health Snags $120M for AI RCM Platform appeared first on MedCity News .
VBC aligns reimbursements to outcomes, emphasizing the quality and effectiveness, not quantity, of healthcare activities. But the same cost constraints driving interest in VBC can also turn it into a liability. The post Why Value-Based Care Only Works If You’ve Tamed Costs appeared first on MedCity News .
A core principle of trauma-informed care is understanding that past and ongoing exposure to stress and trauma can directly shape health outcomes. But by remaining blind to these histories, the medical community severely limits its ability to address the very drivers of the diseases it is trying to cure. The post Medicine Understands Trauma’s Impact, But Rarely Asks About It appeared first on MedCity News .
Drug spending continues to grow, but that doesn’t mean that everyone is getting the medicines that they need. A panel at MedCity News’ Bullseye event discussed the evolution of the prescription drug marketplace. The post A Prescription for Drug Costs: Inject Transparency and Improve Accessibility appeared first on MedCity News .
Health tech investors say the founders who win them over aren’t the ones with all the answers, but the ones who know exactly what they don’t know — and build a team to cover the gap. The post What Health Tech Investors Love in Founders — and What They Can’t Stand appeared first on MedCity News .